Published in Molecular Psychiatry , this is the first study to suggest that the use of high potency cannabis leaves a distinct mark on DNA, providing valuable insights into the biological impact of cannabis use. High potency cannabis is defined as having Delta-9-tetrahydrocannabinol (THC) content of 10 per cent or more. The research also showed the effect of cannabis use on DNA is different in people experiencing their first episode of psychosis compared to users who have never experienced psychosis, suggesting there could be potential for DNA blood tests to help characterise those cannabis users at risk of developing psychosis to inform preventative approaches.
The study was funded by the Medical Research Council, the National Institute for Health and Care Research (NIHR) Maudsley Biomedical Research Centre (BRC) and the NIHR Exeter BRC. Senior author Marta Di Forti, Professor of Drugs, Genes and Psychosis at King's IoPPN said: "With the increasing prevalence of cannabis use and more availability of high potency cannabis, there is a pressing need to better understand its biological impact, particularly on mental health. Our study is the first to show high potency cannabis leaves a unique signature on DNA related to mechanisms around the immune system and energy production.
Future research needs to explore if the DNA signature for current cannabis use, and in particular the one of high potency types, can help identify those users most at risk to develop psychosis, both in rec.